نتائج البحث - Taebo Sim

تنقيح النتائج
  1. 1
    Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8

    Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8 حسب John M. Hatcher, Eric S. Wang, Liv Johannessen, Nicholas Kwiatkowski, Taebo Sim, Nathanael S. Gray

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1

    Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1 حسب Xianming Deng, Qingkai Yang, Nicholas Kwiatkowski, Taebo Sim, Ultan McDermott, Jeffrey Settleman, Jiing-Dwan Lee, Nathanael S. Gray

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout

    A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout حسب Kihyoun Park, Injae Shin, Y. Kim, Hyereen Kang, Soo Jin Oh, Eunkyeong Jang, Taebo Sim, Jeehee Youn, Myung Sik Lee

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

    An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1 حسب Carson C. Thoreen, Seong A. Kang, Jae Won Chang, Qingsong Liu, Jianming Zhang, Yi Gao, Laurie J. Reichling, Taebo Sim, David M. Sabatini, Nathanael S. Gray

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

    Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer حسب Curtis R. Chong, Magda Bahcall, Marzia Capelletti, Takayuki Kosaka, Dalia Ercan, Taebo Sim, Lynette M. Sholl, Mizuki Nishino, Bruce E. Johnson, Nathanael S. Gray, Pasi A. Jänne

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1<i>H</i>)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer

    Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1<i>H</i>)-one as a Highly Potent, Selective Mammalian Target... حسب Qingsong Liu, Jae Won Chang, Jinhua Wang, Seong A. Kang, Carson C. Thoreen, Andrew L. Markhard, Wooyoung Hur, Jianming Zhang, Taebo Sim, David M. Sabatini, Nathanael S. Gray

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Targeted kinase degradation via the KLHDC2 ubiquitin E3 ligase

    Targeted kinase degradation via the KLHDC2 ubiquitin E3 ligase حسب Younghoon Kim, Pooreum Seo, Eunhye Jeon, Inchul You, Kyubin Hwang, Namkyoung Kim, Jason Tse, Ju‐Hyeon Bae, Ha‐Soon Choi, Stephen M. Hinshaw, Nathanael S. Gray, Taebo Sim

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors

    A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors حسب Okram Barun, A. S. Nagle, Francisco Adrián, Christian Lee, Pingda Ren, Xia Wang, Taebo Sim, Yongping Xie, Xing Wang, Gang Xia, Glen Spraggon, Markus Warmuth, Yi Liu, Nathanael S. Gray

    منشور في 2006
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Development of small molecules targeting the pseudokinase Her3

    Development of small molecules targeting the pseudokinase Her3 حسب Sang Min Lim, Ting Xie, Kenneth D. Westover, Scott B. Ficarro, Hyun Seop Tae, Deepak Gurbani, Taebo Sim, Jarrod A. Marto, Pasi A. Jänne, Craig M. Crews, Nathanael S. Gray

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

    Expanding the Diversity of Allosteric Bcr-Abl Inhibitors حسب Xianming Deng, Okram Barun, Qiang Ding, Jianming Zhang, Yongmun Choi, Francisco Adrián, Amy Wojciechowski, Guobao Zhang, Jianwei Che, Badry Bursulaya, Sandra W. Cowan‐Jacob, Gabriele Rummel, Taebo Sim, Nathanael S. Gray

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Covalent Guanosine Mimetic Inhibitors of G12C KRAS

    Covalent Guanosine Mimetic Inhibitors of G12C KRAS حسب Yuan Xiong, Jia Lu, John C. Hunter, Lianbo Li, David A. Scott, Hwan Geun Choi, Sang Min Lim, Anuj Manandhar, Sudershan Reddy Gondi, Taebo Sim, Kenneth D. Westover, Nathanael S. Gray

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function

    Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function حسب Nicholas Kwiatkowski, Nannette Jelluma, P. Filippakopoulos, M. Soundararajan, Michael S. Manak, Mijung Kwon, Hwan Geun Choi, Taebo Sim, Quinn L. Deveraux, Sabine Rottmann, David Pellman, Jagesh V. Shah, Geert J.P.L. Kops, Stefan Knapp, Nathanael S. Gray

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Acquired <i>MET</i>D1228V Mutation and Resistance to MET Inhibition in Lung Cancer

    Acquired <i>MET</i>D1228V Mutation and Resistance to MET Inhibition in Lung Cancer حسب Magda Bahcall, Taebo Sim, Cloud P. Paweletz, Jyoti D. Patel, Ryan S. Alden, Yanan Kuang, Adrian G. Sacher, Nam Doo Kim, Christine Lydon, Mark M. Awad, Michael T. Jaklitsch, Lynette M. Sholl, Pasi A. Jänne, Geoffrey R. Oxnard

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl

    A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl حسب Hwan Geun Choi, Pingda Ren, Francisco Adrián, Fangxian Sun, Hyun Soo Lee, Xia Wang, Qiang Ding, Guobao Zhang, Yongping Xie, Jianming Zhang, Yi Liu, Tove Tuntland, Markus Warmuth, Paul W. Manley, Jürgen Mestan, Nathanael S. Gray, Taebo Sim

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones

    Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones حسب Xianming Deng, Jonathan M. Elkins, Jinwei Zhang, Qingkai Yang, Tatiana Erazo, Néstor Gómez, Hwan Geun Choi, Jinhua Wang, Nicolas Dzamko, Jiing-Dwan Lee, Taebo Sim, Namdoo Kim, Dario R. Alessi, José M. Lizcano, Stefan Knapp, Nathanael S. Gray

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Pharmacological targeting of the pseudokinase Her3

    Pharmacological targeting of the pseudokinase Her3 حسب Ting Xie, Sang Min Lim, Kenneth D. Westover, Michael Dodge, Dalia Ercan, Scott B. Ficarro, Durga Udayakumar, Deepak Gurbani, Hyun Seop Tae, Steven M. Riddle, Taebo Sim, Jarrod A. Marto, Pasi A. Jänne, Craig M. Crews, Nathanael S. Gray

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Inverse Agonist of Nuclear Receptor ERRγ Mediates Antidiabetic Effect Through Inhibition of Hepatic Gluconeogenesis

    Inverse Agonist of Nuclear Receptor ERRγ Mediates Antidiabetic Effect Through Inhibition of Hepatic Gluconeogenesis حسب Don‐Kyu Kim, Gil-Tae Gang, Dongryeol Ryu, Minseob Koh, Yo-Na Kim, Su Sung Kim, Jinyoung Park, Yong‐Hoon Kim, Taebo Sim, In‐Kyu Lee, Cheol Soo Choi, Seung Bum Park, Chul‐Ho Lee, Seung‐Hoi Koo, Hueng-Sik Choi

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)

    Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2) حسب Li Tan, Tyzoon Nomanbhoy, Deepak Gurbani, Matthew P. Patricelli, John C. Hunter, Jiefei Geng, Lina Herhaus, Jianming Zhang, Eduardo Pauls, Youngjin Ham, Hwan Geun Choi, Ting Xie, Xianming Deng, Sara J. Buhrlage, Taebo Sim, Philip Cohen, Gopal P. Sapkota, Kenneth D. Westover, Nathanael S. Gray

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor

    Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor حسب Sang Min Lim, Kenneth D. Westover, Scott B. Ficarro, Rane A. Harrison, Hwan Geun Choi, Michael E. Pacold, Martin A. Carrasco, John C. Hunter, Nam Doo Kim, Ting Xie, Taebo Sim, Pasi A. Jänne, Matthew Meyerson, Jarrod A. Marto, John R. Engen, Nathanael S. Gray

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome

    Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome حسب Suman Rao, Deepak Gurbani, Guangyan Du, Robert A. Everley, Christopher M. Browne, A. Chaikuad, Li Tan, Martin Schröder, Sudershan Reddy Gondi, Scott B. Ficarro, Taebo Sim, Nam Doo Kim, Matthew J. Berberich, Stefan Knapp, Jarrod A. Marto, Kenneth D. Westover, Peter K. Sorger, Nathanael S. Gray

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: